Patient perspectives on factors influencing active surveillance adherence for low-risk prostate cancer: A qualitative study

被引:1
|
作者
Subramanian, Lalita [1 ]
Hawley, Sarah T. [1 ,2 ]
Skolarus, Ted A. [2 ,3 ]
Rankin, Aaron [1 ]
Fetters, Michael D. [4 ]
Witzke, Karla [5 ]
Chen, Jason [1 ]
Radhakrishnan, Archana [1 ,2 ,6 ]
机构
[1] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[2] VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Hlth Serv Res & Dev, Ann Arbor, MI USA
[3] Univ Chicago, Dept Surg, Urol Sect, Chicago, IL USA
[4] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA
[5] MyMichigan Hlth, Dept Urol, Midland, MI USA
[6] Univ Michigan, Dept Internal Med, Div Gen Med, Internal Med, Ann Arbor, MI 48109 USA
来源
CANCER MEDICINE | 2024年 / 13卷 / 01期
关键词
active surveillance; primary care physicians; prostate cancer; quality of life; trust; urologists; MEN; CRITERIA;
D O I
10.1002/cam4.6847
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundProstate cancer is the most common cancer among men in the United States. Treatment guidelines recommend active surveillance for low-risk prostate cancer, which involves monitoring for progression, to avoid or delay definitive treatments and their side effects. Despite increased uptake, adherence to surveillance remains a challenge.MethodsWe conducted semi-structured, qualitative, virtual interviews based on the Theoretical Domains Framework (TDF), with men (15) who were or had been on active surveillance for their low-risk prostate cancer in 2020. Interviews were transcribed and coded under TDF's behavioral theory-based domains. We analyzed domains related to adherence to surveillance using constructivist grounded theory to identify themes influencing decision processes in adherence.ResultsThe TDF domains of emotion, beliefs about consequences, environmental context and resources, and social influences were most relevant to surveillance adherence-. From these four TDF domains, three themes emerged as underlying decision processes: trust in surveillance as treatment, quality of life, and experiences of self and others. Positive perceptions of these three themes supported adherence while negative perceptions contributed to non-adherence (i.e., not receiving follow-up or stopping surveillance). The relationship between the TDF domains and themes provided a theoretical process describing factors impacting active surveillance adherence for men with low-risk prostate cancer.ConclusionsMen identified key factors impacting active surveillance adherence that provide opportunities for clinical implementation and practice improvement. Future efforts should focus on multi-level interventions that foster trust in surveillance as treatment, emphasize quality of life benefits and enhance patients' interpersonal experiences while on surveillance to optimize adherence. Decision processes related to staying on or stopping active surveillance for prostate cancer involved trust in active surveillance as treatment, quality of life and experiences of self and others. Positive perceptions of these three themes supported adherence while negative perceptions contributed to non-adherence.image
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Active surveillance for low-risk prostate cancer - in pursuit of a standardized protocol
    Sosnowski, Roman
    Kamecki, Hubert
    Daneshmand, Siamak
    Rudzinski, Jan K.
    Bjurlin, Marc A.
    Giganti, Francesco
    Roobol, Monique J.
    Klotz, Laurence
    CENTRAL EUROPEAN JOURNAL OF UROLOGY, 2020, 73 (02) : 123 - 126
  • [32] Cognitive and Affective Representations of Active Surveillance as a Treatment Option for Low-Risk Prostate Cancer
    Lyons, Kathleen D.
    Li, Hsin H.
    Mader, Emily M.
    Stewart, Telisa M.
    Morley, Christopher P.
    Formica, Margaret K.
    Perrapato, Scott D.
    Seigne, John D.
    Hyams, Elias S.
    Irwin, Brian H.
    Mosher, Terry
    Hegel, Mark T.
    AMERICAN JOURNAL OF MENS HEALTH, 2017, 11 (01) : 63 - 72
  • [33] Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018
    Briganti, Alberto
    Fossati, Nicola
    Catto, James W. F.
    Cornford, Philip
    Montorsi, Francesco
    Mottet, Nicolas
    Wirth, Manfred
    Van Poppel, Hendrik
    EUROPEAN UROLOGY, 2018, 74 (03) : 357 - 368
  • [34] Prostate volume is an independent predictive factor in selecting low-risk prostate patients for active surveillance
    Yusim, Igor
    Mazor, Elad
    Elsaraya, Nimer
    Gat, Roni
    Novack, Victor
    Mabjeesh, Nicola J.
    FRONTIERS IN UROLOGY, 2022, 2
  • [35] Super active surveillance for low-risk prostate cancer | Opinion: No
    Ghodoussipour, Saum
    Lebastchi, Amir
    Pinto, Peter
    Berger, Andre
    INTERNATIONAL BRAZ J UROL, 2019, 45 (02): : 215 - 219
  • [36] THE ERA OF ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER IS HERE
    Sountoulides, Petros
    Obek, Can
    ARCHIVOS ESPANOLES DE UROLOGIA, 2016, 69 (02): : 49 - 51
  • [37] Surveillance biopsy and active treatment during active surveillance for low-risk prostate cancer
    Katsuyoshi Hashine
    Hiroyuki Iio
    Yoshiteru Ueno
    Shohei Tsukimori
    Iku Ninomiya
    International Journal of Clinical Oncology, 2014, 19 : 531 - 535
  • [38] A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer
    Kim, Simon P.
    Tilburt, Jon C.
    Shah, Nilay D.
    Yu, James B.
    Konety, Badrinath
    Nguuen, Paul L.
    Abouassaly, Robert
    Williams, Stephen B.
    Gross, Cary P.
    CLINICAL GENITOURINARY CANCER, 2019, 17 (03) : E472 - E481
  • [39] Perceived barriers to the adoption of active surveillance in low-risk prostate cancer: a qualitative analysis of community and academic urologists
    Shellie D. Ellis
    Soohyun Hwang
    Emily Morrow
    Kim S. Kimminau
    Kelly Goonan
    Laurie Petty
    Edward Ellerbeck
    J. Brantley Thrasher
    BMC Cancer, 21
  • [40] Can we expand the borders in active surveillance for low-risk prostate cancer?
    Islamoglu, Ekrem
    Kisa, Erdem
    Yucel, Cem
    Celik, Orcun
    Cakmak, Ozgur
    Yalbuzdag, Okan
    Kozacioglu, Zafer
    JOURNAL OF CLINICAL UROLOGY, 2019, 12 (01) : 54 - 59